Massachusetts Society of Clinical Oncologists - FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic NSCLC with a KRASG12C Mutation

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
For Professionals
FDA Approvals
FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic NSCLC with a KRASG12C Mutation

FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic NSCLC with a KRASG12C Mutation

13 Dec 2022 9:30 AM | Katy Monaco (Administrator)

U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI™ (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. Read More.

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329 | email: msco@mms.org